Dong O, Wheeler S, Cruden G, Lee C, Voora D, Dusetzina S, et al. Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. Value Health. 2020;23:61-73 pubmed publisher

Oran I, Cinar C, Bozkaya H, Parildar M, Duman S. Reduced Activity of von Willebrand Factor after Flow-Diverting Stent Implantation for Intracranial Aneurysms: A Link to Acquired von Willebrand Disease?. AJNR Am J Neuroradiol. 2020;41:140-146 pubmed publisher

Kim Y, Her A, Jeong M, Kim B, Hong S, Kim S, et al. Effects of prediabetes on long-term clinical outcomes of patients with acute myocardial infarction who underwent PCI using new-generation drug-eluting stents. Diabetes Res Clin Pract. 2020;160:107994 pubmed publisher

Sim D, Jeong M, Kim H, Gwon H, Seung K, Rha S, et al. Clopidogrel versus Aspirin after Dual Antiplatelet Therapy in Acute Myocardial Infarction Patients Undergoing Drug-Eluting Stenting. Korean Circ J. 2020;50:120-129 pubmed publisher

Kisui F, Fukami T, Nakano M, Nakajima M. Strain and sex differences in drug hydrolase activities in rodent livers. Eur J Pharm Sci. 2020;142:105143 pubmed publisher

Kim Y, Her A, Jeong M, Kim B, Hong S, Kim S, et al. ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents. Angiology. 2020;71:139-149 pubmed publisher

Pustjens T, Streukens B, Vainer J, Gho B, Ruiters A, Stein M, et al. Design and rationale of ischaemia-driven complete revascularisation versus usual care in patients with non-ST-elevation myocardial infarction and multivessel coronary disease: the South Limburg Myocardial Infarction (SLIM) trial. Neth Heart J. 2020;28:75-80 pubmed publisher

Yabe T, Muramatsu T, Tsukahara R, Nakano M, Takimura H, Kawano M, et al. The impact of percutaneous coronary intervention using the novel dynamic coronary roadmap system. Heart Vessels. 2020;35:323-330 pubmed publisher

Witberg G, Zusman O, Bental T, Plakht I, Gabbay H, Gerber Y, et al. Validation of the DAPT score in real-world patients undergoing coronary stent implantation. Int J Cardiol. 2020;300:99-105 pubmed publisher

Martin J, Williams A, Klein M, Sriramoju V, Madan S, Rossi J, et al. Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting. Genet Med. 2020;22:160-169 pubmed publisher

Kitano D, Takayama T, Fukamachi D, Migita S, Morikawa T, Tamaki T, et al. Impact of low-dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug-eluting stent implantation: A randomized comparative study. Catheter Cardiovasc Interv. 2020;95:E8-E16 pubmed publisher

Kwok C, Sirker A, Farmer A, Kontopantelis E, Potts J, Ayyaz Ul Haq M, et al. In-hospital gastrointestinal bleeding following percutaneous coronary intervention. Catheter Cardiovasc Interv. 2020;95:109-117 pubmed publisher

Wolska N, Boncler M, Polak D, Wzorek J, Przygodzki T, Gapińska M, et al. Adenosine Receptor Agonists Exhibit Anti-Platelet Effects and the Potential to Overcome Resistance to P2Y12 Receptor Antagonists. Molecules. 2019;25: pubmed publisher

Nakamura M, Kitazono T, Kozuma K, Sekine T, Nakamura S, Shiosakai K, et al. Prasugrel for Japanese Patients With Ischemic Heart Disease in Long-Term Clinical Practice (PRASFIT-Practice II)　- 1-Year Follow-up Results of a Postmarketing Observational Study. Circ J. 2019;84:101-108 pubmed publisher

Gallus A. After PCI and 3 mo of DAPT, P2Y12-inhibitor monotherapy was noninferior to DAPT at 12 mo. Ann Intern Med. 2019;171:JC53 pubmed publisher

Iglesias J, Heg D, Roffi M, Tüller D, Lanz J, Rigamonti F, et al. Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. J Am Heart Assoc. 2019;8:e013607 pubmed publisher

Ki Y, Kwon S, Kim H, Seo J, Chung W. The Prevention of Contrast Induced Nephropathy by Sarpogrelate: a Prospective Randomized Controlled Clinical Trial. J Korean Med Sci. 2019;34:e261 pubmed publisher

Zhang B, Zhan G, Fang Q, Wang F, Li Y, Zhang Y, et al. Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins. Mol Med Rep. 2019;20:4713-4722 pubmed publisher

Kim Y, Her A, Jeong M, Kim B, Hong S, Kim S, et al. A comparison between statin with ACE inhibitor or ARB therapy in STEMI patients who underwent successful PCI with drug-eluting stents. Atherosclerosis. 2019;289:109-117 pubmed publisher

Iglesias J, Muller O, Heg D, Roffi M, Kurz D, Moarof I, et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet. 2019;394:1243-1253 pubmed publisher

. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019;381:1524-1534 pubmed publisher

Olivier C, Fan J, Askari M, Mahaffey K, Heidenreich P, Perino A, et al. Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019;12:e007604 pubmed publisher

Wester A, Attar R, Mohammad M, Andell P, Hofmann R, Jensen J, et al. Impact of Baseline Anemia in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A Prespecified Analysis From the VALIDATE-SWEDEHEART Trial. J Am Heart Assoc. 2019;8:e012741 pubmed publisher

Kim K, Touchette D, Cavallari L, Ardati A, DiDomenico R. Cost-Effectiveness of Strategies to Personalize the Selection of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome. Cardiovasc Drugs Ther. 2019;33:533-546 pubmed publisher

Chua D, Shalansky S, Sinova A, Mackay M. Factors Affecting Delay in Filling Prescriptions for Dual Antiplatelet Therapy After Coronary Stenting. Can J Cardiol. 2019;35:931-934 pubmed publisher

Staroverov I, Merkulova I, Avetisyan E. [Experience with Prasugrel in the Treatment of Patients with Acute Coronary Syndrome]. Kardiologiia. 2019;59:18-25 pubmed publisher

Hahn J, Song Y, Oh J, Chun W, Park Y, Jang W, et al. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. JAMA. 2019;321:2428-2437 pubmed publisher

Yasuda S, Honda S, Takegami M, Nishihira K, Kojima S, Asaumi Y, et al. Contemporary Antiplatelet Therapy and Clinical Outcomes of Japanese Patients With Acute Myocardial Infarction　- Results From the Prospective Japan Acute Myocardial Infarction Registry (JAMIR). Circ J. 2019;83:1633-1643 pubmed publisher

Kim D, Her S, Park H, Park M, Chang K, Chung W, et al. Association between body mass index and 1-year outcome after acute myocardial infarction. PLoS ONE. 2019;14:e0217525 pubmed publisher

Pufulete M, Harris J, Sterne J, Johnson T, Lasserson D, Mumford A, et al. Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT) in the UK: study protocol for three population-based cohort studies emulating 'target trials' (the ADAPT. BMJ Open. 2019;9:e029388 pubmed publisher

Yaseen I, Farhan H, Abbas H. Clopidogrel non-responsiveness in patients undergoing percutaneous coronary intervention using the VerifyNow test: frequency and predictors. Eur J Hosp Pharm. 2019;26:113-116 pubmed publisher

Gao X, Ge Z, Kong X, Wang Z, Zuo G, Wang F, et al. Clinical Outcomes of Antithrombotic Strategies for Patients with Atrial Fibrillation After Percutaneous Coronary Intervention. Int Heart J. 2019;60:546-553 pubmed publisher

Takamura S, Suzuki N, Ishibashi R, Yukimitsu N, Sasaki K, Terada Y, et al. Long-Term Clinical and Angiographic Outcomes After Implantation of New-Generation Drug-Eluting Stents for Patients on Maintenance Hemodialysis. Int Heart J. 2019;60:521-526 pubmed publisher

Kim Y, Her A, Shin E, Jeong M. Long-term clinical outcome between beta-blocker with ACEI or ARB in patients with NSTEMI who underwent PCI with drug-eluting stents. J Geriatr Cardiol. 2019;16:280-290 pubmed publisher

Cervino G, Fiorillo L, Monte I, De Stefano R, Laino L, Crimi S, et al. Advances in Antiplatelet Therapy for Dentofacial Surgery Patients: Focus on Past and Present Strategies. Materials (Basel). 2019;12: pubmed publisher

Lee C, Choi S, Hwang J, Kim I, Cho Y, Park H, et al. 5-Year Outcomes According to FFR of Left Circumflex Coronary Artery After Left Main Crossover Stenting. JACC Cardiovasc Interv. 2019;12:847-855 pubmed publisher

Nishihara M. Inhibitory Effect of Vonoprazan on the Metabolism of [14C]Prasugrel in Human Liver Microsomes. Eur J Drug Metab Pharmacokinet. 2019;: pubmed publisher

Shinouchi K, Ueda Y, Kato T, Nishida H, Ozaki T, Kosugi S, et al. Relation of Chronic Total Occlusion to In-Hospital Mortality in the Patients With Sudden Cardiac Arrest Due to Acute Coronary Syndrome. Am J Cardiol. 2019;123:1915-1920 pubmed publisher

Tokimasa S, Kitahara H, Nakayama T, Fujimoto Y, Shiba T, Shikama N, et al. Multicenter research of bleeding risk between prasugrel and clopidogrel in Japanese patients with coronary artery disease undergoing percutaneous coronary intervention. Heart Vessels. 2019;: pubmed publisher

Ge Z, Baber U, Claessen B, Chandrasekhar J, Chandiramani R, Li S, et al. Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry. J Thromb Thrombolysis. 2019;48:42-51 pubmed publisher

Komosa A, Lesiak M, Krasinski Z, Grygier M, Siniawski A, Skorupski W, et al. Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis. Thromb Haemost. 2019;119:1000-1020 pubmed publisher

Bianco M, Gravinese C, Cerrato E, Núñez Gil I, Destefanis P, Luciano A, et al. Management of aspirin intolerance in patients undergoing percutaneous coronary intervention: the role of mono-antiplatelet therapy. A retrospective, multicenter, study. Minerva Cardioangiol. 2019;: pubmed publisher

Kwon O, Kang S, Lee J, Ahn J, Lee C, Kang D, et al. Comparative effectiveness of different contemporary drug-eluting stents in routine clinical practice: a multigroup propensity score analysis using data from the stent-specific, multicenter, prospective registries. Coron Artery Dis. 2019;30:255-262 pubmed publisher

Winter M, Schneeweiss T, Cremer R, Biesinger B, Hengstenberg C, Prüller F, et al. Platelet reactivity patterns in patients treated with dual antiplatelet therapy. Eur J Clin Invest. 2019;:e13102 pubmed publisher

Kim Y, Her A, Jeong M, Kim B, Lee S, Hong S, et al. One-year clinical outcomes between biodegradable-polymer-coated biolimus-eluting stent and durable-polymer-coated drug-eluting stents in STEMI patients with multivessel coronary artery disease undergoing culprit-only or multivessel PCI. Atherosclerosis. 2019;284:102-109 pubmed publisher

Ishihara T, Tsujimura T, Okuno S, Iida O, Asai M, Masuda M, et al. Early- and middle-phase arterial repair following bioresorbable- and durable-polymer drug-eluting stent implantation: An angioscopic study. Int J Cardiol. 2019;285:27-31 pubmed publisher

Kim Y, Her A, Jeong M, Kim B, Hong S, Ahn C, et al. A comparison of the impact of current smoking on 2-year major clinical outcomes of first- and second-generation drug-eluting stents in acute myocardial infarction: Data from the Korea Acute Myocardial Infarction Registry. Medicine (Baltimore). 2019;98:e14797 pubmed publisher

Kimmelstiel C, Stevenson R, Nguyen N, Van Doren L, Zhang P, Perkins J, et al. Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel. Thromb Res. 2019;177:59-69 pubmed publisher

Redfors B, Dworeck C, Haraldsson I, Angerås O, Odenstedt J, Ioanes D, et al. Pretreatment with P2Y12 receptor antagonists in ST-elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry. Eur Heart J. 2019;40:1202-1210 pubmed publisher

Khan M, Memon M, Usman M, Alnaimat S, Khan S, Khan A, et al. Prasugrel vs. Ticagrelor for Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs. 2019;: pubmed publisher

Silvain J, Rakowski T, Lattuca B, Liu Z, Bolognese L, Goldstein P, et al. Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2019;73:906-914 pubmed publisher

Droppa M, Vaduganathan M, Venkateswaran R, Singh A, Szumita P, Roberts R, et al. Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y12 inhibition from the IABP-SHOCK II trial. Resuscitation. 2019;: pubmed publisher

Costa F, van Klaveren D, Feres F, James S, Räber L, Pilgrim T, et al. Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. J Am Coll Cardiol. 2019;73:741-754 pubmed publisher

Briguori C, Visconti G, Golino M, Focaccio A, Signoriello G. Sirolimus-eluting BiOSS LIM dedicated bifurcation stent in the treatment of unprotected distal left main stenosis. Catheter Cardiovasc Interv. 2019;94:323-331 pubmed publisher

Witberg G, Plakht Y, Bental T, Feldman B, Leventer Roberts M, Levi A, et al. Development of a risk score for predicting the benefit versus harm of extending dual antiplatelet therapy beyond 6 months following percutaneous coronary intervention for stable coronary artery disease. PLoS ONE. 2019;14:e0209661 pubmed publisher

Parker W, Orme R, Hanson J, Stokes H, Bridge C, Shaw P, et al. Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. Platelets. 2019;30:148-157 pubmed publisher

Lee C, Kang D, Han M, Hur S, Rha S, Her S, et al. Differential cutoff points and clinical impact of stent parameters of various drug-eluting stents for predicting major adverse clinical events: An individual patient data pooled analysis of seven stent-specific registries and 17,068 patients. Int J Cardiol. 2019;282:17-23 pubmed publisher

Rothenbühler M, Valgimigli M, Odutayo A, Frigoli E, Leonardi S, Vranckx P, et al. Association of acute kidney injury and bleeding events with mortality after radial or femoral access in patients with acute coronary syndrome undergoing invasive management: secondary analysis of a randomized clinical trial. Eur Heart J. 2019;40:1226-1232 pubmed publisher

Nakamura M, Kozuma K, Kitazono T, Iizuka T, Sekine T, Shiosakai K, et al. Prasugrel for Japanese Patients With Ischemic Heart Disease in Long-Term Clinical Practice (PRASFIT-Practice II)　- A 3-Month Interim Analysis of a Postmarketing Observational Study. Circ J. 2019;83:637-646 pubmed publisher

Faggioni M, Baber U, Chandrasekhar J, Sartori S, Weintraub W, Rao S, et al. Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. Catheter Cardiovasc Interv. 2019;94:53-60 pubmed publisher

Amano H, Noike R, Saito D, Yabe T, Watanabe I, Okubo R, et al. Plaque characteristics and slow flow during percutaneous coronary intervention of irregular protrusion by optical coherence tomography. Heart Vessels. 2019;34:1076-1085 pubmed publisher

Baber U, Leisman D, Cohen D, Gibson C, Henry T, Dangas G, et al. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. Circ Cardiovasc Qual Outcomes. 2019;12:e004945 pubmed publisher

Toba T, Shinke T, Otake H, Sugizaki Y, Takeshige R, Onishi H, et al. Impact of dual antiplatelet therapy with adjusted-dose prasugrel on mid-term vascular response in patients undergoing elective percutaneous coronary intervention with everolimus-eluting stents. Heart Vessels. 2019;34:936-947 pubmed publisher

Zimarino M, Briguori C, Amat Santos I, Radico F, Barbato E, Chieffo A, et al. Mid-term outcomes after percutaneous interventions in coronary bifurcations. Int J Cardiol. 2019;283:78-83 pubmed publisher

Verdoia M, Pergolini P, Nardin M, Rolla R, Barbieri L, Marino P, et al. Prevalence and predictors of high-on treatment platelet reactivity during prasugrel treatment in patients with acute coronary syndrome undergoing stent implantation. J Cardiol. 2019;73:198-203 pubmed publisher

Sim D, Jeong M, Kim H, Gwon H, Seung K, Rha S, et al. Association of potent P2Y12 blockers with ischemic and bleeding outcomes in non-ST-segment elevation myocardial infarction. J Cardiol. 2019;73:142-150 pubmed publisher

Boncler M, Wzorek J, Wolska N, Polak D, Watala C, Rozalski M. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y12 antagonists. Vascul Pharmacol. 2019;113:47-56 pubmed publisher

Kambayashi A, Dressman J. Predicting the Changes in Oral Absorption of Weak Base Drugs Under Elevated Gastric pH Using an In Vitro-In Silico-In Vivo Approach: Case Examples-Dipyridamole, Prasugrel, and Nelfinavir. J Pharm Sci. 2019;108:584-591 pubmed publisher

Ge Z, Baber U, Claessen B, Farhan S, Chandrasekhar J, Li S, et al. The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. Catheter Cardiovasc Interv. 2019;93:E112-E119 pubmed publisher

Venetsanos D, Sederholm Lawesson S, Frobert O, Omerovic E, Henareh L, Robertsson L, et al. Sex-related response to bivalirudin and unfractionated heparin in patients with acute myocardial infarction undergoing percutaneous coronary intervention: A subgroup analysis of the VALIDATE-SWEDEHEART trial. Eur Heart J Acute Cardiovasc Care. 2019;8:502-509 pubmed publisher

Erlinge D, Koul S, Omerovic E, Frobert O, Linder R, Danielewicz M, et al. Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2019;8:492-501 pubmed publisher

Smolders E, Ter Horst P, Wolters S, Burger D. Cardiovascular Risk Management and Hepatitis C: Combining Drugs. Clin Pharmacokinet. 2019;58:565-592 pubmed publisher

Brugaletta S, Cequier A, Alfonso F, Iniguez A, Romaní S, Serra A, et al. MAGnesium-based bioresorbable scaffold and vasomotor function in patients with acute ST segment elevation myocardial infarction: The MAGSTEMI trial: Rationale and design. Catheter Cardiovasc Interv. 2019;93:64-70 pubmed publisher

Ohno Y, Kitahara H, Fujii K, Kohno Y, Ariyoshi N, Nishi T, et al. High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis. J Cardiol. 2019;73:51-57 pubmed publisher

Raposeiras Roubín S, Abu Assi E, D Ascenzo F, Fernández Barbeira S, Kinnaird T, Ariza Solé A, et al. Annual Incidence of Confirmed Stent Thrombosis and Clinical Predictors in Patients With ACS Treated With Ticagrelor or Prasugrel. Rev Esp Cardiol (Engl Ed). 2019;72:298-304 pubmed publisher

Staudacher D, Putz V, Heger L, Reinöhl J, Hortmann M, Zelenkofske S, et al. Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes. Eur Heart J Acute Cardiovasc Care. 2019;8:520-526 pubmed publisher

Kawai Y, Miyoshi T, Nakamura K, Shokoku G, Yamamoto K, Ono T, et al. Association between changes in platelet reactivity during elective percutaneous coronary intervention and periprocedural myocardial infarction: A pilot study. J Cardiol. 2018;: pubmed publisher

Anantha Narayanan M, Anugula D, Gujjula N, Reddy Y, Baskaran J, Kaushik M, et al. Bivalirudin versus heparin in percutaneous coronary intervention-a systematic review and meta-analysis of randomized trials stratified by adjunctive glycoprotein IIb/IIIa strategy. J Thorac Dis. 2018;10:3341-3360 pubmed publisher

Choi H, Kim M, Sim D, Hong Y, Kim J, Jeong M, et al. Serum Copeptin Levels Predict Clinical Outcomes After Successful Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction. Ann Lab Med. 2018;38:538-544 pubmed publisher

Head S, Milojevic M, Daemen J, Ahn J, Boersma E, Christiansen E, et al. Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization. J Am Coll Cardiol. 2018;72:386-398 pubmed publisher

Mizuno M, Ito Y, Sugidachi A. A novel porcine model of thrombotic myocardial infarction with cardiac dysfunction sensitive to dual antiplatelet therapy. Eur J Pharmacol. 2018;834:103-108 pubmed publisher

McQuillan C, Gray A, Kearney A, Menown I. Advances in Clinical Cardiology 2017: A Summary of Key Clinical Trials. Adv Ther. 2018;35:899-927 pubmed publisher

Yetgin T, Boersma E, Smits P, de Vries A, Huijskens E, Zijlstra F, et al. One-year efficacy and safety of routine prasugrel in patients with acute coronary syndromes treated with percutaneous coronary intervention: results of the prospective rijnmond collective cardiology research study. Neth Heart J. 2018;26:393-400 pubmed publisher

Rashid M, Lawson C, Potts J, Kontopantelis E, Kwok C, Bertrand O, et al. Incidence, Determinants, and Outcomes of Left and Right Radial Access Use in Patients Undergoing Percutaneous Coronary Intervention in the United Kingdom: A National Perspective Using the BCIS Dataset. JACC Cardiovasc Interv. 2018;11:1021-1033 pubmed publisher

Yasuda S, Kaikita K, Ogawa H, Akao M, Ako J, Matoba T, et al. Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group study. Int J Cardiol. 2018;265:108-112 pubmed publisher

Kim Y, Oh S, Jeong M, Ahn Y, Kim J, Hong Y, et al. Comparison of short-term clinical outcomes between Resolute Onyx zotarolimus-eluting stents and everolimus-eluting stent in patients with acute myocardial infarction: Results from the Korea Acute Myocardial infarction Registry (KAMIR). Cardiol J. 2018;: pubmed publisher

Bundhun P, Huang F. Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis. BMC Cardiovasc Disord. 2018;18:78 pubmed publisher

Katayama Y, Kubo T, Ino Y, Kameyama T, Matsuo Y, Kitabata H, et al. The relationship between timing of prasugrel pretreatment and in-stent thrombus immediately after percutaneous coronary intervention for acute coronary syndrome: an optical coherence tomography study. Heart Vessels. 2018;33:1159-1167 pubmed publisher

Kolkailah A, Alreshq R, Muhammed A, Zahran M, Anas El Wegoud M, Nabhan A. Transradial versus transfemoral approach for diagnostic coronary angiography and percutaneous coronary intervention in people with coronary artery disease. Cochrane Database Syst Rev. 2018;4:CD012318 pubmed publisher

Kim M, Jeong M, Sim D, Hong Y, Kim J, Ahn Y, et al. Comparison of Clinical Outcomes Between Ticagrelor and Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction　- Results From the Korea Acute Myocardial Infarction Registry-National Institutes of Health. Circ J. 2018;82:1866-1873 pubmed publisher

Chalouhi N, Patel P, Atallah E, Starke R, Chitale A, Lang M, et al. Low Yield of Cerebral Angiography in Adequately Occluded Aneurysms After Flow Diversion. Neurosurgery. 2018;83:1294-1297 pubmed publisher

Verdoia M, Pergolini P, Barbieri L, Rolla R, Nardin M, Negro F, et al. Impact of pre-procedural dual antiplatelet therapy on periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions with adjunctive tirofiban. Thromb Res. 2018;164:17-23 pubmed publisher

Bellemain Appaix A, Bégué C, Bhatt D, Ducci K, Harrington R, Roe M, et al. The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis. EuroIntervention. 2018;14:78-85 pubmed publisher

Zeitouni M, Silvain J, Guedeney P, Kerneis M, Yan Y, Overtchouk P, et al. Periprocedural myocardial infarction and injury in elective coronary stenting. Eur Heart J. 2018;39:1100-1109 pubmed publisher

Sudarshana D, Konstantinou E, Arepalli S, Silva F, Schachat A, Ehlers J, et al. The Prevalence of Adverse Ocular Hemorrhagic Events in Patients Utilizing Oral Anticoagulant and Antiplatelet Therapy in Routine Clinical Practice. Ophthalmic Surg Lasers Imaging Retina. 2018;49:27-34 pubmed publisher

Gargiulo G, Ariotti S, Vranckx P, Leonardi S, Frigoli E, Ciociano N, et al. Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management: Data From the Randomized MATRIX-Access Trial. JACC Cardiovasc Interv. 2018;11:36-50 pubmed publisher

Xanthopoulou I, Bei I, Bampouri T, Barampoutis N, Moulias A, Davlouros P, et al. Absence of differential effect of ticagrelor versus prasugrel maintenance dose on endothelial function in patients with stable coronary artery disease. Hellenic J Cardiol. 2018;59:338-343 pubmed publisher

Ozawa T, Suda M, Ikegami R, Takano T, Wakasugi T, Yanagawa T, et al. Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome. Int Heart J. 2018;59:21-26 pubmed publisher

Otani T, Sawano H, Natsukawa T, Matsuoka R, Nakashima T, Takahagi M, et al. D-dimer predicts bleeding complication in out-of-hospital cardiac arrest resuscitated with ECMO. Am J Emerg Med. 2018;36:1003-1008 pubmed publisher

Cavallari L, Lee C, Beitelshees A, Cooper Dehoff R, Duarte J, Voora D, et al. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2018;11:181-191 pubmed publisher

Effron M, Wang T, Fonarow G, Henry T, Zettler M, Baker B, et al. The safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary intervention in community practice: Insights from the TRANSLATE-ACS study. Catheter Cardiovasc Interv. 2018;91:242-250 pubmed publisher

Deharo P, Quilici J, Camoin Jau L, Johnson T, Bassez C, Bonnet G, et al. Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study. JACC Cardiovasc Interv. 2017;10:2560-2570 pubmed publisher

Raco D. After PCI in AF, dual antithrombotic therapy with dabigatran reduced bleeding compared with triple therapy. Ann Intern Med. 2017;167:JC70 pubmed publisher

Bates E. Guided early deescalation of antiplatelet treatment was noninferior to usual prasugrel care in PCI-treated ACS. Ann Intern Med. 2017;167:JC69 pubmed publisher

Tilemann L, Mohr S, Preusch M, Chorianopoulos E, Giannitsis E, Katus H, et al. Platelet function monitoring for stent thrombosis in critically III patients with an acute Coronary syndrome. J Interv Cardiol. 2017;: pubmed publisher

Itkonen M, Tornio A, Filppula A, Neuvonen M, Neuvonen P, Niemi M, et al. Clopidogrel but not Prasugrel Significantly Inhibits the CYP2C8-mediated Metabolism of Montelukast in Humans. Clin Pharmacol Ther. 2017;: pubmed publisher

Higa A, Hoshi H, Yanagisawa Y, Ito E, Morisawa G, Imai J, et al. Evaluation system for arrhythmogenic potential of drugs using human-induced pluripotent stem cell-derived cardiomyocytes and gene expression analysis. J Toxicol Sci. 2017;42:755-761 pubmed publisher

Watti H, Dahal K, Zabher H, Katikaneni P, Modi K, Abdulbaki A. Comparison of prasugrel and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized and non-randomized studies. Int J Cardiol. 2017;249:66-72 pubmed publisher

Song C, Sukul D, Seth M, Dupree J, Khandelwal A, Dixon S, et al. Ninety-Day Readmission and Long-Term Mortality in Medicare Patients (?65 Years) Treated With Ticagrelor Versus Prasugrel After Percutaneous Coronary Intervention (from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium). Am J Cardiol. 2017;120:1926-1932 pubmed publisher

Alexopoulos D, Katogiannis K, Sfantou D, Lekakis J. Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?. Platelets. 2017;:1-10 pubmed publisher

Lowenstern A, Newby L. In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events. Ann Intern Med. 2017;167:JC28 pubmed publisher

Toyota T, Shiomi H, Morimoto T, Natsuaki M, Kimura T. Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: A comparison between the DAPT study and 9 other trials evaluating DAPT duration. PLoS ONE. 2017;12:e0174502 pubmed publisher

Yamauchi T, Masai T, Fujii K, Sawa Y, Shirai S, Kamigaki M, et al. Long-term clinical results of acute myocardial infarction at the left main trunk requiring percutaneous cardiopulmonary support. J Artif Organs. 2017;20:303-310 pubmed publisher

Naganuma T, Kawamoto H, Panoulas V, Latib A, Tanaka A, Mitomo S, et al. Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold versus everolimus-eluting stent for coronary bifurcation lesions. Int J Cardiol. 2017;246:26-31 pubmed publisher

Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390:1747-1757 pubmed publisher

Erlinge D, Omerovic E, Frobert O, Linder R, Danielewicz M, Hamid M, et al. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. N Engl J Med. 2017;377:1132-1142 pubmed publisher

Alraies M, Lee S, Lipinski M, Buchanan K, Steinvil A, Rogers T, et al. Effect of Bleeding Risk on Type of Stent Used in Patients Presenting With Acute Coronary Syndrome. Am J Cardiol. 2017;120:1272-1278 pubmed publisher

Kandzari D, Smits P, Love M, Ben Yehuda O, Banai S, Robinson S, et al. Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: Primary Results From the BIONICS Trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis). Circulation. 2017;136:1304-1314 pubmed publisher

Rudolph T, Fuchs A, Klinke A, Schlichting A, Friedrichs K, Hellmich M, et al. Prasugrel as opposed to clopidogrel improves endothelial nitric oxide bioavailability and reduces platelet-leukocyte interaction in patients with unstable angina pectoris: A randomized controlled trial. Int J Cardiol. 2017;248:7-13 pubmed publisher

Uzu K, Shinke T, Otake H, Takaya T, Osue T, Iwasaki M, et al. Morphological and pharmacological determinants of peri-procedural myocardial infarction following elective stent implantation: Optical coherence tomography sub-analysis of the PRASFIT-Elective study. J Cardiol. 2017;70:545-552 pubmed publisher

Kim Y, Her A, Rha S, Choi B, Shim M, Choi S, et al. Routine Angiographic Follow-Up versus Clinical Follow-Up after Percutaneous Coronary Intervention in Acute Myocardial Infarction. Yonsei Med J. 2017;58:720-730 pubmed publisher

Cuisset T, Deharo P, Quilici J, Johnson T, Deffarges S, Bassez C, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38:3070-3078 pubmed publisher

Bagai A, Peterson E, McCoy L, Effron M, Zettler M, Stone G, et al. Association of measured platelet reactivity with changes in P2Y12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of. Am Heart J. 2017;187:19-28 pubmed publisher

Coons J, Iasella C, Chanas T, Wang N, Williams K, Boyd A, et al. Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery System. Ann Pharmacother. 2017;51:649-655 pubmed publisher

Lau E, Braunwald E, Murphy S, Wiviott S, Bonaca M, Husted S, et al. Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2017;69:1549-1559 pubmed publisher

Sciahbasi A, Frigoli E, Sarandrea A, Rothenbühler M, Calabro P, Lupi A, et al. Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD-Matrix Trial. J Am Coll Cardiol. 2017;69:2530-2537 pubmed publisher

Wang W, Liu J, Fang J, Liu Y, An T, Zou M, et al. The optimal discontinuation of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention with drug-eluting stents: A meta-analysis of randomized trials. Int J Cardiol. 2017;235:73-86 pubmed publisher

Koltowski L, Tomaniak M, Aradi D, Huczek Z, Filipiak K, Kochman J, et al. Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective PCI patients: A pilot study: ONSIDE TEST pilot. Cardiol J. 2017;24:284-292 pubmed publisher

Verlinden N, Coons J, Iasella C, Kane Gill S. Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention: An Evaluation of Prasugrel or Ticagrelor Versus Clopidogrel. J Cardiovasc Pharmacol Ther. 2017;22:546-551 pubmed publisher

Kim Y, Her A, Rha S, Choi B, Shim M, Choi S, et al. Routine angiographic follow-up versus clinical follow-up in patients with multivessel coronary artery diseases following percutaneous coronary intervention with drug-eluting stents: a nested case-control study within a Korean population. Coron Artery Dis. 2017;28:307-314 pubmed publisher

Geraci S, Kawamoto H, Caramanno G, Ruparelia N, Capodanno D, Brugaletta S, et al. Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry. JACC Cardiovasc Interv. 2017;10:560-568 pubmed publisher

Zhang Y, Peti Peterdi J, Brandes A, Riquier Brison A, Carlson N, Muller C, et al. Prasugrel suppresses development of lithium-induced nephrogenic diabetes insipidus in mice. Purinergic Signal. 2017;13:239-248 pubmed publisher

Montone R, Niccoli G, Minelli S, Fracassi F, Vetrugno V, Aurigemma C, et al. Clinical outcome and correlates of coronary microvascular obstruction in latecomers after acute myocardial infarction. Int J Cardiol. 2017;236:30-35 pubmed publisher

Teren A, Kirsten H, Beutner F, Scholz M, Holdt L, Teupser D, et al. Alteration of Multiple Leukocyte Gene Expression Networks is Linked with Magnetic Resonance Markers of Prognosis After Acute ST-Elevation Myocardial Infarction. Sci Rep. 2017;7:41705 pubmed publisher

Hess C, Kaltenbach L, Doll J, Cohen D, Peterson E, Wang T. Race and Sex Differences in Post-Myocardial Infarction Angina Frequency and Risk of 1-Year Unplanned Rehospitalization. Circulation. 2017;135:532-543 pubmed publisher

Hochholzer W, Kleiner P, Younas I, Valina C, Löffelhardt N, Amann M, et al. Randomized Comparison of Oral P2Y12-Receptor Inhibitor Loading Strategies for Transitioning From Cangrelor: The ExcelsiorLOAD2 Trial. JACC Cardiovasc Interv. 2017;10:121-129 pubmed publisher

Fujii T, Nakano M, Ohno Y, Nakazawa G, Shinozaki N, Matsukage T, et al. Collateral filling efficiency of comorbid chronic total occlusion segment on short-term mortality in ST-elevation myocardial infarction. Int J Cardiol. 2017;230:346-352 pubmed publisher

Jakubowski J, HOPPE C, Zhou C, Smith B, Brown P, Heath L, et al. Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia. Thromb Haemost. 2017;117:580-588 pubmed publisher

Koskinas K, Taniwaki M, Rigamonti F, Heg D, Roffi M, Tüller D, et al. Impact of Patient and Lesion Complexity on Long-Term Outcomes Following Coronary Revascularization With New-Generation Drug-Eluting Stents. Am J Cardiol. 2017;119:501-507 pubmed publisher

Zhang L, Lu J, Dong W, Tian H, Feng W, You H, et al. Meta-analysis of Comparison of the Newer P2Y12 Inhibitors (Oral Preparation or Intravenous) to Clopidogrel in Patients With Acute Coronary Syndrome. J Cardiovasc Pharmacol. 2017;69:147-155 pubmed publisher

Bonello L, Laine M, Puymirat E, Lemesle G, Thuny F, Paganelli F, et al. Timing of Coronary Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes and Clinical Outcomes: An Updated Meta-Analysis. JACC Cardiovasc Interv. 2016;9:2267-2276 pubmed publisher

Asher E, Mansour J, Wheeler A, Kendrick D, Cunningham M, Parikh S, et al. Cost awareness decreases total percutaneous coronary intervention procedural cost: The SHOPPING (Show How Options in Price for Procedures Can Be Influenced Greatly) trial. Catheter Cardiovasc Interv. 2017;89:1207-1212 pubmed publisher

Sato T, Namba Y, Kashihara Y, Tanaka M, Fuke S, Yumoto A, et al. Clinical significance of platelet reactivity during prasugrel therapy in patients with acute myocardial infarction. J Cardiol. 2017;70:35-40 pubmed publisher

Birnbaum Y, Birnbaum G, Birnbaum I, Nylander S, Ye Y. Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine. Cardiovasc Drugs Ther. 2016;30:539-550 pubmed

MAKIKALLIO T, Holm N, Lindsay M, Spence M, Erglis A, Menown I, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet. 2016;388:2743-2752 pubmed publisher

Jatene T, Biering Sørensen T, Nochioka K, Mangione F, Hansen K, Sørensen R, et al. Frequency of Cardiac Death and Stent Thrombosis in Patients With Chronic Obstructive Pulmonary Disease Undergoing Percutaneous Coronary Intervention (from the BASKET-PROVE I and II Trials). Am J Cardiol. 2017;119:14-19 pubmed publisher

Aggarwal V, Armstrong E, Liu W, Maddox T, Ho P, Carey E, et al. Prasugrel Use Following PCI and Associated Patient Outcomes: Insights From the National VA CART Program. Clin Cardiol. 2016;39:578-584 pubmed publisher

Ranucci M, Baryshnikova E, Pistuddi V, Menicanti L, Frigiola A. The effectiveness of 10 years of interventions to control postoperative bleeding in adult cardiac surgery. Interact Cardiovasc Thorac Surg. 2017;24:196-202 pubmed publisher

Makam R, Erskine N, McManus D, Lessard D, Gore J, Yarzebski J, et al. Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction. Am J Cardiol. 2016;118:1792-1797 pubmed publisher

Flierl U, Zauner F, Sieweke J, Berliner C, Napp L, Tillmanns J, et al. Efficacy of prasugrel administration immediately after percutaneous coronary intervention in ST-elevation myocardial infarction. Thromb Haemost. 2017;117:99-104 pubmed publisher

Rauzi F, Kirkby N, Edin M, Whiteford J, Zeldin D, Mitchell J, et al. Aspirin inhibits the production of proangiogenic 15(S)-HETE by platelet cyclooxygenase-1. FASEB J. 2016;30:4256-4266 pubmed

Björquist A, Di Buduo C, Femia E, Storey R, Becker R, Balduini A, et al. Studies of the interaction of ticagrelor with the P2Y13 receptor and with P2Y13-dependent pro-platelet formation by human megakaryocytes. Thromb Haemost. 2016;116:1079-1088 pubmed

Harle T, Zeymer U, Hochadel M, Zahn R, Kerber S, Zrenner B, et al. Real-world use of fractional flow reserve in Germany: results of the prospective ALKK coronary angiography and PCI registry. Clin Res Cardiol. 2017;106:140-150 pubmed publisher

Beigel R, Iakobishvili Z, Shlomo N, Segev A, Witberg G, Zahger D, et al. Real-World Use of Novel P2Y12 Inhibitors in Patients with Acute Myocardial Infarction: A Treatment Paradox. Cardiology. 2017;136:21-28 pubmed

Umemura K, Iwaki T. The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers. Clin Pharmacol Drug Dev. 2016;5:480-487 pubmed publisher

Federspiel J, Anstrom K, Xian Y, McCoy L, Effron M, Faries D, et al. Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention. JAMA Cardiol. 2016;1:655-65 pubmed publisher

Siller Matula J, Specht S, Kubica J, Alexopoulos D, De Caterina R, Hobl E, et al. Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients. Br J Clin Pharmacol. 2016;82:1343-1350 pubmed publisher

Shah R, Rogers K, Ahmed A, King B, Rao S. Effect of Post-Primary Percutaneous Coronary Intervention Bivalirudin Infusion on Acute Stent Thrombosis: Meta-Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2016;9:1313-20 pubmed publisher

Bernlochner I, Mayer K, Orban M, Morath T, Jaitner J, Rössner L, et al. Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study. Platelets. 2016;27:796-804 pubmed

Tello Montoliu A, Rivera J, Hernandez Romero D, Silvente A, Jover E, Quintana M, et al. Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold. Platelets. 2016;27:777-783 pubmed

Bennett J, Adriaenssens T, Desmet W, Dubois C. Complex bifurcation lesions: Randomized comparison of a fully bioresorbable modified t stenting strategy versus bifurcation reconstruction with a dedicated self-expanding stent in combination with bioresorbable scaffolds, an OCT study: Rationale and . Catheter Cardiovasc Interv. 2016;88:843-853 pubmed publisher

Chandrasekhar J, Baber U, Sartori S, Faggioni M, Aquino M, Kini A, et al. Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study. Catheter Cardiovasc Interv. 2017;89:629-637 pubmed publisher

Tröbs M, Achenbach S, Röther J, Klinghammer L, Schlundt C. Bioresorbable vascular scaffold thrombosis in a consecutive cohort of 550 patients. Catheter Cardiovasc Interv. 2016;88:872-880 pubmed publisher

de Waard G, Hollander M, Teunissen P, Jansen M, Eerenberg E, Beek A, et al. Changes in Coronary Blood Flow After Acute Myocardial Infarction: Insights From a Patient Study and an Experimental Porcine Model. JACC Cardiovasc Interv. 2016;9:602-13 pubmed publisher

Yudi M, Clark D, Farouque O, Eccleston D, Andrianopoulos N, Duffy S, et al. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Intern Med J. 2016;46:559-65 pubmed publisher

Smith K, Peterson J, Arnold P, Camarata P, Whittaker T, Abraham M. A case series of dural venous sinus stenting in idiopathic intracranial hypertension: association of outcomes with optical coherence tomography. Int J Neurosci. 2017;127:145-153 pubmed

Hochholzer W, Amann M, Titov A, Younas I, Löffelhardt N, Riede F, et al. Randomized Comparison of Different Thienopyridine Loading Strategies in Patients Undergoing Elective Coronary Intervention: The ExcelsiorLOAD Trial. JACC Cardiovasc Interv. 2016;9:219-227 pubmed publisher

La Manna A, Chisari A, Giacchi G, Capodanno D, Longo G, Di Silvestro M, et al. Everolimus-eluting bioresorbable vascular scaffolds versus second generation drug-eluting stents for percutaneous treatment of chronic total coronary occlusions: Technical and procedural outcomes from the GHOST-CTO registry. Catheter Cardiovasc Interv. 2016;88:E155-E163 pubmed publisher

Baker N, Escarcega R, Lipinski M, Magalhães M, Koifman E, Kiramijyan S, et al. Active Versus Passive Anchoring Vascular Closure Devices Following Percutaneous Coronary Intervention: A Safety and Efficacy Comparative Analysis. J Interv Cardiol. 2016;29:108-12 pubmed publisher

Kurokawa T, Fukami T, Yoshida T, Nakajima M. Arylacetamide Deacetylase is Responsible for Activation of Prasugrel in Human and Dog. Drug Metab Dispos. 2016;44:409-16 pubmed publisher

Jackson L, Ju C, Zettler M, Messenger J, Cohen D, Stone G, et al. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. JACC Cardiovasc Interv. 2015;8:1880-9 pubmed publisher

Hess C, Wang T, McCoy L, Messenger J, Effron M, Zettler M, et al. Unplanned Inpatient and Observation Rehospitalizations After Acute Myocardial Infarction: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndro. Circulation. 2016;133:493-501 pubmed publisher

Braun D, Knipper A, Orban M, Sibbing D, Petzold T, Braun S, et al. Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy). Thromb Res. 2016;137:72-78 pubmed publisher

Larmore C, Effron M, Molife C, DeKoven M, Zhu Y, Lu J, et al. "Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States. Catheter Cardiovasc Interv. 2016;88:535-544 pubmed publisher

Mega J, Close S, Wiviott S, Man M, Duvvuru S, Walker J, et al. PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes. J Thromb Thrombolysis. 2016;41:374-83 pubmed publisher

Bailleul C, Puymirat E, Aissaoui N, Schiele F, Ducrocq G, Coste P, et al. Factors Associated With Infarct-Related Artery Patency Before Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (from the FAST-MI 2010 Registry). Am J Cardiol. 2016;117:17-21 pubmed publisher

Sabaté M, Brugaletta S, Cequier A, Iñiguez A, Serra A, Jiménez Quevedo P, et al. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. Lancet. 2016;387:357-366 pubmed publisher

Scavone M, Femia E, Caroppo V, Cattaneo M. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate does not impair the capacity of platelet to synthesize thromboxane A2. Eur Heart J. 2016;37:3347-3356 pubmed publisher

Nishikawa M, Isshiki T, Kimura T, Ogawa H, Yokoi H, Miyazaki S, et al. No association between on-treatment platelet reactivity and bleeding events following percutaneous coronary intervention and antiplatelet therapy: A post hoc analysis. Thromb Res. 2015;136:947-54 pubmed publisher

Rigobello C, Barden A, Steppe M. LC method for determination of prasugrel and mass spectrometry detection for thermal and alkaline degradation products. Pharmazie. 2015;70:515-21 pubmed

Lee J, Jung J, Park K, Shin E, Oh S, Bae J, et al. Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial. Trials. 2015;16:409 pubmed publisher

Helft G, Steg P, Le Feuvre C, Georges J, Carrie D, Dreyfus X, et al. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. Eur Heart J. 2016;37:365-74 pubmed publisher

Geisler T, Booth J, Tavlaki E, Karathanos A, Müller K, Droppa M, et al. High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel. PLoS ONE. 2015;10:e0135037 pubmed publisher

Greenberg G, Bental T, Lev E, Assali A, Vaknin Assa H, Kornowski R. A Comparative Matched Analysis of Clinical Outcomes between Transradial versus Transfemoral Percutaneous Coronary Intervention. Isr Med Assoc J. 2015;17:360-4 pubmed

Räber L, Klingenberg R, Heg D, Kelbæk H, Roffi M, Tüller D, et al. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study. JACC Cardiovasc Interv. 2015;8:1064-1074 pubmed publisher

Kerneis M, Silvain J, Abtan J, Hauguel M, Barthélémy O, Payot L, et al. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction. Arch Cardiovasc Dis. 2015;108:502-10 pubmed publisher

Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nishikawa M, et al. Impact of Arterial Access Route on Bleeding Complications in Japanese Patients Undergoing Percutaneous Coronary Intervention- Insight From the PRASFIT Trial. Circ J. 2015;79:1928-37 pubmed publisher

Bonello L, Laine M, Cluzel M, Frere C, Mancini J, Hasan A, et al. Comparison of Ticagrelor Versus Prasugrel to Prevent Periprocedural Myonecrosis in Acute Coronary Syndromes. Am J Cardiol. 2015;116:339-43 pubmed publisher

Lee Y, Jin C, Kim M, Guo L, Cho Y, Park K, et al. Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction. Circ J. 2015;79:1248-54 pubmed publisher

Saia F, Komukai K, Capodanno D, Sirbu V, Musumeci G, Boccuzzi G, et al. Eroded Versus Ruptured Plaques at the Culprit Site of STEMI: In Vivo Pathophysiological Features and Response to Primary PCI. JACC Cardiovasc Imaging. 2015;8:566-575 pubmed publisher

So D, Wells G, McPherson R, Labinaz M, Le May M, Glover C, et al. A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. Pharmacogenomics J. 2016;16:71-8 pubmed publisher

Lemesle G, Schurtz G, Bauters C, Hamon M. High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. J Thromb Haemost. 2015;13:931-42 pubmed publisher

Lambrechts K, Pontier J, Mazur A, Theron M, Buzzacott P, Wang Q, et al. Mechanism of action of antiplatelet drugs on decompression sickness in rats: a protective effect of anti-GPIIbIIIa therapy. J Appl Physiol (1985). 2015;118:1234-9 pubmed publisher

Kimura T, Isshiki T, Ogawa H, Yokoi H, Yamaguchi T, Ikeda Y. Randomized, Double-Blind, Dose-Finding, Phase II Study of Prasugrel in Japanese Patients Undergoing Elective Percutaneous Coronary Intervention. J Atheroscler Thromb. 2015;22:557-69 pubmed publisher

Nakamura M, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al. Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: post-hoc analysis of the randomized PRASFIT-ACS study. Int J Cardiol. 2015;182:541-8 pubmed publisher

Johnston L, La Flamme A, Larsen P, Harding S. Prasugrel inhibits platelet-enhanced pro-inflammatory CD4+ T cell responses in humans. Atherosclerosis. 2015;239:283-6 pubmed publisher

Gencer B, Rodondi N, Auer R, Räber L, Klingenberg R, Nanchen D, et al. Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes. Eur J Intern Med. 2015;26:56-62 pubmed publisher

Holmberg M, Tornio A, Hyvärinen H, Neuvonen M, Neuvonen P, Backman J, et al. Effect of grapefruit juice on the bioactivation of prasugrel. Br J Clin Pharmacol. 2015;80:139-45 pubmed publisher

Bulluck H, Kwok C, Ryding A, Loke Y. Safety of short-term dual antiplatelet therapy after drug-eluting stents: An updated meta-analysis with direct and adjusted indirect comparison of randomized control trials. Int J Cardiol. 2015;181:331-9 pubmed publisher

Montalescot G, Collet J, Ecollan P, Bolognese L, Ten Berg J, Dudek D, et al. Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study. J Am Coll Cardiol. 2014;64:2563-2571 pubmed publisher

Eisen A, Lerman Shivek H, Perl L, Rechavia E, Leshem Lev D, Zemer Wassercug N, et al. Circulating reticulated platelets over time in patients with myocardial infarction treated with prasugrel or ticagrelor. J Thromb Thrombolysis. 2015;40:70-5 pubmed publisher

Gandhi S, Zile B, Tan M, Saranu J, Bucci C, Yan A, et al. Increased uptake of guideline-recommended oral antiplatelet therapy: insights from the Canadian acute coronary syndrome reflective. Can J Cardiol. 2014;30:1725-31 pubmed publisher

Lussana F, di Marco F, Terraneo S, Parati M, Razzari C, Scavone M, et al. Effect of prasugrel in patients with asthma: results of PRINA, a randomized, double-blind, placebo-controlled, cross-over study. J Thromb Haemost. 2015;13:136-41 pubmed publisher

Marsillach J, Suzuki S, Richter R, McDonald M, Rademacher P, MacCoss M, et al. Human valacyclovir hydrolase/biphenyl hydrolase-like protein is a highly efficient homocysteine thiolactonase. PLoS ONE. 2014;9:e110054 pubmed publisher

Orban M, Mayer K, Morath T, Bernlochner I, Hadamitzky M, Braun S, et al. Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry. Thromb Haemost. 2014;112:1190-7 pubmed publisher

Paarup Dridi N, Johansson P, Lønborg J, Clemmensen P, Radu M, Qayyum A, et al. Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome. Platelets. 2015;26:521-9 pubmed publisher

Ohno K, Tanaka H, Samata N, Jakubowski J, Tomizawa A, Mizuno M, et al. Platelet activation biomarkers in Berkeley sickle cell mice and the response to prasugrel. Thromb Res. 2014;134:889-94 pubmed publisher

Garg P, Wijeysundera H, Yun L, Cantor W, Ko D. Practice patterns and trends in the use of medical therapy in patients undergoing percutaneous coronary intervention in Ontario. J Am Heart Assoc. 2014;3: pubmed publisher

McNeice A, McAleavey N, Menown I. Advances in clinical cardiology. Adv Ther. 2014;31:837-60 pubmed publisher

Delesque Touchard N, Pflieger A, Bonnet Lignon S, Millet L, Salel V, Boldron C, et al. SAR216471, an alternative to the use of currently available P2Y?? receptor inhibitors?. Thromb Res. 2014;134:693-703 pubmed publisher

Bakal J, Roe M, Ohman E, Goodman S, Fox K, Zheng Y, et al. Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. Eur Heart J. 2015;36:385-92a pubmed publisher

Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J. 2014;78:1684-92 pubmed

Kazui M, Hagihara K, Izumi T, Ikeda T, Kurihara A. Hepatic microsomal thiol methyltransferase is involved in stereoselective methylation of pharmacologically active metabolite of prasugrel. Drug Metab Dispos. 2014;42:1138-45 pubmed publisher

Diodati J, Saucedo J, Cardillo T, Jakubowski J, Henneges C, Effron M, et al. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial. Thromb Haemost. 2014;112:311-22 pubmed publisher